Cardiology

Top Story

MATRIX: Event rates not different for bivalirudin, heparin after PCI for ACS

September 1, 2015

Read the Perspective from Johanne Silvain, MD

LONDON — In patients with ACS undergoing PCI, rates of major adverse cardiac events and net adverse clinical events were similar between patients assigned bivalirudin and those assigned heparin, according to new findings from the MATRIX study.

Among patients assigned bivalirudin (Angiomax, The Medicines Company), patients who had a post-PCI bivalirudin infusion did not have better rates of NACE, urgent target vessel revascularization or definite stent thrombosis compared with those who had no post-PCI infusion, Marco Valgimigli, MD, PhD, from Thoraxcenter, Erasmus Medical Center, Rotterdam, the Netherlands, said during a press conference at the European Society of Cardiology Congress.

Meeting News CoveragePerspective

Central sleep apnea device increases mortality in patients with HF

September 1, 2015
LONDON — Adaptive servo-ventilation had no significant impact on the primary composite endpoint of all-cause mortality, lifesaving CV intervention or unplanned…
VIDEO: Optimal duration of DAPT a continued focus of research Meeting News CoverageVideo

VIDEO: Optimal duration of DAPT a continued focus of research

August 31, 2015
LONDON — In this video, Deepak L. Bhatt, MD, MPH, Chief Medical Editor of Cardiology Today’s Intervention, discusses results of the OPTIDUAL Hot Line trial…
Gerard Helft Meeting News Coverage

OPTIDUAL: Extended DAPT not superior to 12-month therapy

August 31, 2015
LONDON — Extending dual antiplatelet therapy with clopidogrel and aspirin for 48 months was not superior to 12 months of therapy for the reduction of net adverse…
VIDEO: SCOT study addresses CV risk conferred by NSAIDs Meeting News CoverageVideo

VIDEO: SCOT study addresses CV risk conferred by NSAIDs

August 31, 2015
LONDON — In this video, Richard A. Chazal, MD, FACC, medical director of the Heart and Vascular Institute at Lee Memorial Health System, Fort Myers, Florida, and…
More News Headlines »
CME
Managing Today's EP Challenges with NOAC Use

Managing Today's EP Challenges with NOAC Use

This activity is supported by independent educational grants from Boehringer Ingelheim Pharmaceuticals, Inc. and Daiichi Sankyo, Inc.

This engaging activity featuring a superb faculty provides electrophysiologists and others with the best information…
More »
Meeting News Coverage Video
VIDEO: SCOT study addresses CV risk conferred by NSAIDs

VIDEO: SCOT study addresses CV risk conferred by NSAIDs

August 31, 2015
LONDON — In this video, Richard A. Chazal, MD, FACC, medical director of the Heart and Vascular Institute at Lee…
More »
CME
PCI in ACS: Deciding Among Clopidogrel, Prasugrel, or Ticagrelor

PCI in ACS: Deciding Among Clopidogrel, Prasugrel, or Ticagrelor

This activity is supported by an educational grant from Daiichi Sankyo, Inc. and Lilly USA, LLC

It is estimated that in the United States, each year, over 780,000 persons will experience an acute coronary syndrome…
More »